(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BACKGROUND: Cholecystokinin (CCK) is a gastrointestinal hormone that has been proposed as a potential therapeutic option for obesity-diabetes. As such, (pGlu-Gln)-CCK-8 is an N-terminally modified CCK-8 analogue with improved biological effectiveness over the native peptide.METHODS: The current study has examined the in vitro stability, biological activity and in vivo therapeutic applicability of a novel second generation mini-PEGylated form of (pGlu-Gln)-CCK-8, (pGlu-Gln)-CCK-8[mPEG].RESULTS: (pGlu-Gln)-CCK-8[mPEG] was completely resistant to enzymatic degradation and in addition displayed similar insulinotropic (p
Original languageEnglish
Pages (from-to)4009-4016
JournalBBA - General Subjects
Volume1830
Issue number8
DOIs
Publication statusPublished - 10 Apr 2013

Fingerprint Dive into the research topics of '(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes'. Together they form a unique fingerprint.

  • Cite this